NRx Pharmaceuticals, Inc. (NRXP)
| Market Cap | 104.70M +116.8% |
| Revenue (ttm) | 3.39M |
| Net Income | -23.48M |
| EPS | -0.78 |
| Shares Out | 43.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 435,098 |
| Open | 2.390 |
| Previous Close | 2.360 |
| Day's Range | 2.360 - 2.500 |
| 52-Week Range | 1.620 - 5.055 |
| Beta | 2.06 |
| Analysts | Strong Buy |
| Price Target | 38.75 (+1,501.24%) |
| Est. Earnings | Nov 24, 2026 |
About NRXP
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NRXP stock is "Strong Buy." The 12-month stock price target is $38.75, which is an increase of 1,501.24% from the latest price.
News
NRx Pharmaceuticals commences selling of preservative-free ketamine
NRx Pharmaceuticals (NRXP) announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018...
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression...
NRx Pharmaceuticals Proxy statement: Proxy filing
NRx Pharmaceuticals filed a proxy statement on November 5, 2026, providing details for shareholder voting and corporate governance matters.
NRx Pharmaceuticals Proxy statement: Proxy filing
NRx Pharmaceuticals filed a proxy statement on November 5, 2026, providing details for shareholder voting and corporate governance matters.
NRx Pharmaceuticals Transcript: FDA announcement
FDA approved preservative-free ketamine ahead of its goal date, marking the first approved product and a move toward commercial launch. Plans center on U.S. supply, a five-million-vial launch stock, and staged expansion through 2027.
NRx Pharmaceuticals Press release: FDA announcement
NRx Pharmaceuticals issued a press release on October 30, 2026, disclosing material business information to investors.
NRx Pharmaceuticals announces FDA approval for Ketamine ANDA
NRx Pharmaceuticals (NRXP) announced that the FDA has approved the company’s Abbreviated New Drug Application, or ANDA, for Preservative-Free Ketamine. The approval comes ahead of the FDA-announced No...
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
WILMINGTON, Del., Oct. 30, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression...
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Company to issue press release before market open; conference call to follow at 8:30 a.m. ET Company to issue press release before market open; conference call to follow at 8:30 a.m. ET
NRx Pharmaceuticals says NY Times retracts ‘false statements’ about NRx
NRx Pharmaceuticals (NRXP) stated: “Three days after the New York Times was notified of the false nature of its report, the paper corrected its article to state, ‘In a petition…
NRx Pharmaceuticals calls NY Times report ‘knowingly false,’ demands retraction
“The report by the New York Times alleging that NRx Pharmaceuticals (NRXP) submitted no data on the toxicity of Benzethonium Chloride is knowingly false and NRx has demanded a retraction,”…
NRx Pharmaceuticals’ Ketafree leads FDA approval race, NY Times reports
NRx Pharmaceuticals (NRXP) is advancing Ketafree, a preservative-free ketamine formulation, and is seeking FDA approval while arguing that benzethonium chloride, a preservative used in most ketamine p...
NRx Pharmaceuticals completes three process validation lots of Ketamine
NRx Pharmaceuticals (NRXP) announced completion of three process validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 Generic Drug User...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NM...
Psychedelic: NRx Pharmaceuticals receives FDA labeling review letter
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a FDA request, a scientific advisor agreement and a board appointment. NRX…
NRx receives FDA review letter for Ketamine product requesting minor changes
NRx Pharmaceuticals (NRXP) announced the receipt of a “Discipline Review Letter” from the FDA requesting “minor” changes to the submitted label for NRx’s Preservative-Free Ketamine product. The letter...
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by F...
NRx Pharmaceuticals awarded initial $11.18M DARPA prime contract
NRx Defense Systems announced the award of an initial $11,177,757.27 contract issued by the Defense Advanced Research Projects Agency, DARPA, a Branch of the United States Department of War. The…
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are ...
NRx Pharmaceuticals says FDA reclassifies ANDA amendment to ‘minor’
NRx Pharmaceuticals (NRXP) announced that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the company that the amendment…
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announc...
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env i...
NRx Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Key advances include a preservative-free ketamine (KETAFREE) nearing FDA decision, integration of robotic TMS for depression, and phase II success for NRX-101 in reducing suicidality and akathisia. Commercial launch and profitability are targeted for mid-next year.
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announc...
NRx Pharmaceuticals Transcript: Moody Capital Disruptive Growth & Life Science Conference
A newly acquired biotech is advancing monoclonal antibody therapies targeting endogenous retroviruses for ALS and other diseases, with clinical trials planned by 2027 and strong patent protection. Partnerships span NIH and major research institutes, and a $5M crowdfunding raise is underway.